GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PetMed Express Inc (NAS:PETS) » Definitions » Return-on-Tangible-Equity

PetMed Express (PetMed Express) Return-on-Tangible-Equity : -11.52% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is PetMed Express Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PetMed Express's annualized net income for the quarter that ended in Dec. 2023 was $-8.1 Mil. PetMed Express's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $70.4 Mil. Therefore, PetMed Express's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -11.52%.

The historical rank and industry rank for PetMed Express's Return-on-Tangible-Equity or its related term are showing as below:

PETS' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.5   Med: 25.24   Max: 35.96
Current: -3.5

During the past 13 years, PetMed Express's highest Return-on-Tangible-Equity was 35.96%. The lowest was -3.50%. And the median was 25.24%.

PETS's Return-on-Tangible-Equity is ranked worse than
72.76% of 536 companies
in the Healthcare Providers & Services industry
Industry Median: 10.215 vs PETS: -3.50

PetMed Express Return-on-Tangible-Equity Historical Data

The historical data trend for PetMed Express's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetMed Express Return-on-Tangible-Equity Chart

PetMed Express Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.35 19.66 17.75 14.23 4.53

PetMed Express Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -0.75 -3.75 -0.34 -11.52

Competitive Comparison of PetMed Express's Return-on-Tangible-Equity

For the Pharmaceutical Retailers subindustry, PetMed Express's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetMed Express's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PetMed Express's Return-on-Tangible-Equity falls into.



PetMed Express Return-on-Tangible-Equity Calculation

PetMed Express's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=5.14/( (122.59+104.106 )/ 2 )
=5.14/113.348
=4.53 %

PetMed Express's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-8.108/( (79.039+61.711)/ 2 )
=-8.108/70.375
=-11.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


PetMed Express  (NAS:PETS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


PetMed Express Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of PetMed Express's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


PetMed Express (PetMed Express) Business Description

Traded in Other Exchanges
Address
420 South Congress Avenue, Suite 100, Delray Beach, FL, USA, 33445
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.
Executives
Gian Fulgoni director
Christine Chambers officer: CFO 1501 1ST AVENUE SOUTH, STE. 600, SEATTLE WA 98134
Mathew N Hulett director, officer: CEO & President 1621 NORTH KENT STREET, SUITE 1200, ARLINGTON VA 22209
Campbell Leslie C.g. director C/O COUPA SOFTWARE INC., 1855 S. GRANT STREET, SAN MATEO CA 94402
Diana G Purcel director C/O FAMOUS DVES OF AMERICA INC, 8091 WALLACE ROAD, EDEN PRAIRIE MN 55344
Moseley Mark Bradley Jr other: Chief Technology Info Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Daniel Job Pingree other: Chief Marketing Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Sandra Yvette Campos director 4900 E DUBLIN GRANVILLE RD, COLUMBUS OH 43081
Jacqueline Paula Smith other: Vice President of People 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Carolyn Carden other: VP of Product 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Peter Cobb director DSW, INC., 810 DSW DRIVE, COLUMBUS OH 43219
Jodi Watson director 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Frank J Formica director 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069
Bruce S Rosenbloom officer: Chief Financial Officer 6401 CONGRESS AVENUE, SUITE 250, BOCA RATON FL 33487
Menderes Akdag director, officer: Chief Executive Officer 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069